We develop a new Bayesian approach of sample size determination (SSD) for the design of non-inferiority clinical trials. We extend the fitting and sampling priors of Wang and Gelfand (2002) to Bayesian SSD with a focus on controlling the type I error and power. Historical data are incorporated via a hierarchical modeling approach as well as the power prior approach of Ibrahim and Chen (2000). Various properties of the proposed Bayesian SSD methodology are examined and a simulation-based computational algorithm is developed. The proposed methodology is applied to the design of a non-inferiority medical device clinical trial with historical data from previous trials
This paper develops Bayesian sample size formulae for experiments comparing two groups, where releva...
In non-inferiority trials, the goal is to show how an experimental treatment is statistically and cl...
In the last decade, the number of clinical trials using Bayesian methods has grown dramatically. Now...
We develop a new Bayesian approach of sample size determination (SSD) for the design of non-inferior...
We consider the sample size determination (SSD) problem, which is a basic yet extremely important as...
Non inferiority clinical trials have gained immense popularity within the last decades. Such trials ...
Includes bibliographical references (p. 123-128).The process of conducting a pharmaceutical clinical...
Perhaps the most valuable contribution of Bayesian methods to health care evaluation involves study ...
Non-inferiority trials, which aim to demonstrate that a test product is not worse than a competitor ...
Obstacles sometimes limit enrollment in randomized clinical trials of an exper- imental product vers...
This paper considers the design and interpretation of clinical trials comparing treatments for condi...
There is growing interest in Bayesian clinical trial designs with informative prior distributions, e...
Bayesian analysis of a non-inferiority trial is advantageous in allowing direct probability statemen...
The sample size of a prospective clinical study aimed at validation of a diagnostic biomarker-based ...
Early phase, or phase I and phase II, trials are the first step in testing new medicines that have b...
This paper develops Bayesian sample size formulae for experiments comparing two groups, where releva...
In non-inferiority trials, the goal is to show how an experimental treatment is statistically and cl...
In the last decade, the number of clinical trials using Bayesian methods has grown dramatically. Now...
We develop a new Bayesian approach of sample size determination (SSD) for the design of non-inferior...
We consider the sample size determination (SSD) problem, which is a basic yet extremely important as...
Non inferiority clinical trials have gained immense popularity within the last decades. Such trials ...
Includes bibliographical references (p. 123-128).The process of conducting a pharmaceutical clinical...
Perhaps the most valuable contribution of Bayesian methods to health care evaluation involves study ...
Non-inferiority trials, which aim to demonstrate that a test product is not worse than a competitor ...
Obstacles sometimes limit enrollment in randomized clinical trials of an exper- imental product vers...
This paper considers the design and interpretation of clinical trials comparing treatments for condi...
There is growing interest in Bayesian clinical trial designs with informative prior distributions, e...
Bayesian analysis of a non-inferiority trial is advantageous in allowing direct probability statemen...
The sample size of a prospective clinical study aimed at validation of a diagnostic biomarker-based ...
Early phase, or phase I and phase II, trials are the first step in testing new medicines that have b...
This paper develops Bayesian sample size formulae for experiments comparing two groups, where releva...
In non-inferiority trials, the goal is to show how an experimental treatment is statistically and cl...
In the last decade, the number of clinical trials using Bayesian methods has grown dramatically. Now...